Close Menu

NEW YORK (GenomeWeb) – Oxford Gene Technologies plans to develop a suite of narrowly targeted, disease-specific next-generation sequencing panels for the translational market in cancer and inherited disease, and also is working on an array-based test for noninvasive prenatal screening, company officials told GenomeWeb.

Last week, the Oxfordshire, UK-based molecular genetics firm launched an ovarian cancer panel and a library prep kit that Executive VP of Research and Development John Anson said would be the first of a number of NGS-based panels.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.